Insmed Incorporated

NasdaqGS:INSM

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

United States

Market Cap

USD 19.50 B

Share Price

USD 102.68

Avg Daily Volume

2,289,787

Change (1 day)

3.24%

Change (1 year)

58.68%

Change (YTD)

48.73%

Insmed Incorporated Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2025: 4.62

Insmed Incorporated Current Ratio is 4.62 for the Trailing 12 Months (TTM) ending March 31, 2025, a 31.84% change year over year. Current ratio represents the short-term liquidity measurement, showing current assets' coverage of liabilities. Higher ratio implies better ability to meet short-term obligations.

Insmed Incorporated Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2024 was 3.50, a -40.57% change year over year.
Insmed Incorporated Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 5.89, a -22.47% change year over year.
Insmed Incorporated Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 7.60, a 10.35% change year over year.
Insmed Incorporated Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 6.89, a -1.42% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Current Ratio	Interest Coverage Ratio	Return on Capital Employed (ROCE)	Return on Equity (ROE)

NasdaqGS: INSM

Insmed Incorporated

CEO	Mr. William H. Lewis J.D., M.B.A.
IPO Date	June 1, 2000
Location	United States
Headquarters	700 US Highway 202/206
Employees	1,271
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.